Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy

NCT06028633 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06028633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06028633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy
Lead sponsor
Peking University First Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2023
Completion date
October 31, 2026
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-squamous non-small-cell lung cancer, metastatic non-squamous non small cell lung cancer, recurrent non-squamous non-small cell lung cancer